Biom'up announced the completion of the 2018 scale-up of its manufacturing facility to meet commercial demand for HEMOBLASTTM Bellows in the US and selected national markets in the EU. To meet the encouraging market demand, the Company efficiently executed a rigorous scale-up of its manufacturing facility in France, including upgrading and fully validating 6 key internal and outsourced processes allowing for a much larger throughput and increased shipments of devices to the US and EU markets. As a consequence, the Company's product output grew to more than 4,000 units of HEMOBLAST Bellows in October 2018. This number is expected to grow to 7,000 units per month by H1 2019, fulfilling the Company's production commitment to investors made at the time of their IPO in October 2017.